Iovance Biotherapeutics Inc
IOVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.53B
Close$
$-0.19
101.4% downside
Current Fair Value
101.4% downsideOvervalued by 101.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.53 Billion |
|---|---|
| Enterprise Value | $6.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.76 |
| Outstanding Shares | 450,189,000 |
Return
| Return on Equity | -39.33% |
|---|---|
| Return on Assets | -31.62% |
| Return on Invested Capital | -35.73% |
Valuation & Multiples
| P/E Ratio | -20.89 |
|---|---|
| PEG | 36.24 |
| Price to Sales | - |
| Price to Book Ratio | 13.62 |
| Enterprise Value to Revenue | 19.89 |
| Enterprise Value to EBIT | -22.37 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$87.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$115.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9213▼ 14.45% |
|---|---|
| Total Calls | 4,486,900▲ 41.97% |
| Total Puts | 4,133,900▲ 22.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.37%▲ 0.07% |
|---|---|
| Total Invested | $1.21B▲ 27.72% |
| Investors Holding | 305▲ 3.00% |
ESG Score
No data
About Iovance Biotherapeutics Inc
975 employees
CEO: Maria Fardis Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to id...